Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$628M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$567M |
| 3 |
Biogen
BIIB
|
+$405M |
| 4 |
UnitedHealth
UNH
|
+$392M |
| 5 |
Walmart Inc
WMT
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$451M |
| 2 |
PepsiCo
PEP
|
+$382M |
| 3 |
Philip Morris
PM
|
+$256M |
| 4 |
Roku
ROKU
|
+$252M |
| 5 |
RHT
Red Hat Inc
RHT
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.91% |
| 2 | Technology | 12.35% |
| 3 | Consumer Discretionary | 10.31% |
| 4 | Financials | 9.99% |
| 5 | Consumer Staples | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGMO
2801
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $606K | ﹤0.01% |
67,000
-559,800
| -89% | -$6.28M |
|
2802
BioCryst Pharmaceuticals
BCRX
$2.28B
| $604K | ﹤0.01% |
+210,815
| New | +$656K |
|
|
NEOS
2803
DELISTED
Neos Therapeutics, Inc
NEOS
| $604K | ﹤0.01% |
408,162
+266,607
| +188% | +$431K |
|
|
SECO
2804
DELISTED
Secoo Holding Limited ADR
SECO
| $602K | ﹤0.01% |
8,990
-3,000
| -25% | -$222K |
|
2805
AXT Inc
AXTI
$3.95B
| $598K | ﹤0.01% |
168,000
-14,467
| -8% | -$55.7K |
|
|
RRTS
2806
DELISTED
RoadRunner Transportation Systems, Inc.
RRTS
| $597K | ﹤0.01% |
57,588
+12,500
| +28% | +$122K |
|
2807
Mannatech
MTEX
$9.24M
| $595K | ﹤0.01% |
34,017
+4,620
| +16% | +$75.4K |
|
|
MBAI
2808
Check-Cap
MBAI
$8.19M
| $593K | ﹤0.01% |
15,778
+405
| +3% | +$16.5K |
|
|
GNCA
2809
DELISTED
Genocea Biosciences, Inc.
GNCA
| $590K | ﹤0.01% |
203,362
+36,975
| +22% | +$126K |
|
2810
ProQR Therapeutics
PRQR
$243M
| $589K | ﹤0.01% |
102,300
+84,500
| +475% | +$675K |
|
2811
Vanguard FTSE All-World ex-US ETF
VEU
$66.6B
| $589K | ﹤0.01% |
11,800
-28,000
| -70% | -$1.4M |
|
|
MDP
2812
DELISTED
Meredith Corporation
MDP
| $587K | ﹤0.01% |
+16,000
| New | +$745K |
|
|
GLIBA
2813
DELISTED
GCI Liberty, Inc. Class A Common Stock (DE)
GLIBA
| $584K | ﹤0.01% |
+9,410
| New | +$582K |
|
|
FLXN
2814
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $581K | ﹤0.01% |
+42,400
| New | +$503K |
|
|
GSUM
2815
DELISTED
Gridsum Holding Inc.
GSUM
| $581K | ﹤0.01% |
346,026
-761
| -0.2% | -$1.82K |
|
|
CRESY
2816
Cresud
CRESY
$795M
| $580K | ﹤0.01% |
104,824
+72,447
| +224% | +$549K |
|
2817
Boston Omaha
BOC
$428M
| $579K | ﹤0.01% |
29,200
+17,500
| +150% | +$373K |
|
|
TDAY
2818
USA Today Co
TDAY
$1.27B
| $576K | ﹤0.01% |
+65,404
| New | +$597K |
|
2819
Stagwell
STGW
$2.07B
| $576K | ﹤0.01% |
204,400
-28,000
| -12% | -$70.2K |
|
|
TCON
2820
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $576K | ﹤0.01% |
6,439
+393
| +7% | +$40.3K |
|
2821
Waste Management
WM
$90.6B
| $575K | ﹤0.01% |
+5,000
| New | +$584K |
|
2822
Twin Disc
TWIN
$329M
| $574K | ﹤0.01% |
54,193
+7,000
| +15% | +$83K |
|
|
SMIT
2823
DELISTED
Schmitt Industries Inc
SMIT
| $572K | ﹤0.01% |
261,048
+700
| +0.3% | +$1.49K |
|
2824
First Trust Natural Gas ETF
FCG
$647M
| $571K | ﹤0.01% |
+49,800
| New | +$610K |
|
2825
OneSpan
OSPN
$574M
| $571K | ﹤0.01% |
39,370
-70,299
| -64% | -$1.02M |
|
Similar funds
Renaissance Technologies's Q3 2019 Portfolio in Review
As of Q3 2019, Renaissance Technologies held 3,920 positions worth $118B, up 4% from $114B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Renaissance Technologies deployed $5.29B of net new capital in Q3 2019, opening 406 new positions and adding to 1,848 existing holdings. Its largest new stake was UnitedHealth: 1,624,826 shares worth $353M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $451M trimmed.
- Renaissance Technologies's largest Q3 2019 buy was UnitedHealth: 1,624,826 shares worth $353M.
- Renaissance Technologies added most to Celgene Corp in Q3 2019, an estimated $628M increase.
- Renaissance Technologies's biggest Q3 2019 reduction was Apple, cutting an estimated $451M.
- Renaissance Technologies fully exited Red Hat Inc in Q3 2019, selling an estimated $248M.
- Renaissance Technologies's ten largest holdings make up 11% of its $118B portfolio in Q3 2019.
- Renaissance Technologies opened 406 new positions and closed 522 in Q3 2019.
- Renaissance Technologies's portfolio value rose 4% quarter-over-quarter to $118B.
Based on Renaissance Technologies's 13F filing for Q3 2019, filed 13 Nov 2019.